GMEX vs NVDA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GMEX exhibits critical financial instability, highlighted by a weak Piotroski F-Score of 3/9 and a catastrophic price collapse of over 99% in the last year. While the company maintains a low debt-to-equity ratio and a strong current ratio, these liquidity metrics are overshadowed by a total loss of shareholder value and negative profitability. The reported dividend yield of 163.30% is a massive red flag, typically indicating a dividend trap or a severe price correction rather than a sustainable return. Overall, the deterministic health scores and technical trend (0/100) suggest a company in a state of collapse.
NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.
Compare Another Pair
Related Comparisons
GMEX vs NVDA: Head-to-Head Comparison
This page compares GMEX Robotics Corporation (GMEX) and NVIDIA Corporation (NVDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.